|New Threads Only:|
|New Threads & Replies:|
Forum List » Value Ideas and Strategies|
Share and discuss value investing ideas and investing strategies.
Thermo Fisher Scientific - An Instrumental Play ... Barrons
Posted by: Dr. Paul Price (IP Logged)
Date: May 23, 2009 06:18AM
MONDAY, MAY 25, 2009
By MICHAEL SANTOLI
An uncharacteristic business downdraft has hit lab-equipment giant Thermo Fisher Scientific -- and its shares. Why both could rebound.
THE MARCH OF SCIENCE HALTS FOR NO RECESSION. But in a particularly bruising downturn, the march slows.
This lesson has become clear to Thermo Fisher Scientific , the leader in laboratory equipment and supplies, a company that once expanded sales and profits in steady lock step, but since late last year has seen its business downshift uncharacteristically.
Many global companies last quarter would have welcomed the 15% drop in earnings per share that Thermo Fisher experienced, but minus signs are unfamiliar to the company and its investors.
Thermo Fisher's shares (ticker: TMO) sank from more than 60 last summer to the mid-30s, and earnings forecasts for 2009 have been tempered from once-aggressive to more-reasonable levels. As a result, the instrument maker, a former growth-stock favorite that had always sported a premium valuation multiple, is now available at an attractive price.
The company, produced by the 2006 merger of Thermo Electron and Fisher Scientific, sells a comprehensive array of laboratory equipment, instruments, supplies and services to the health-care, biotechnology, university and industrial sectors. Its products are a crucial, if uncelebrated, part of drug discovery, chemical development and environmental-quality projects.
The idea behind the merger was to unite the old Thermo's research-equipment offerings with the consumable lab goods sold through the old Fisher's ubiquitous trade catalogs. The result was an attractive balance between consumables and capital goods, and a revenue stream that came from several end markets, as the accompanying charts confirm.
Thermo Fisher's chief executive, Marijn Dekkers, who led Thermo Electron beginning in 2002 and engineered the merger, says the deal's rationale is playing out well. "We have made progress with our larger clients in persuading them to centralize and standardize their purchasing," he says, rather than allowing, say, each scientist in every lab at a hospital or university to decide on what kinds of products to buy.
Since the deal concluded, free cash flow has surged to $1.2 billion in 2008, a level the company expects to match or slightly exceed in 2009, despite an anticipated dip in earnings this year to a range of $2.80 to $3.10 per share from last year's $3.13.
This essentially means the company converts nearly all earnings to free cash flow -- a sign of a potent business model. Assuming free cash flow gets to the anticipated $2.80 a share, the stock would sport a free-cash-flow yield above 7.5%.
Though Thermo Fisher fell to 42nd from eighth place in the latest Barron's 500 ranking of large companies, based on return on capital, the company remained in the top 10% of Corporate America by this measure. Thermo Fischer has a $15 billion stock-market value. Its $500 million in net debt (debt minus cash) is less than half its annual cash flow.
Ironically, at a time when so many companies are being punished for their wounded, debt-stressed balance sheets, investors are pressing Thermo Fisher to spend its cash reserves or take on more debt to repurchase more of its stock. There remains $400 million in a current buyback plan, but Wall Street wants more -- a stance that could be short-sighted.
"Investors are preoccupied with what to do with our balance sheet," Dekkers says. "They are saying, 'Why not buy the heck out of the stock at these levels?' "
Instead, Dekkers insists, he would "like to keep our powder dry. We are in a fragmented industry and we would like to be able to do acquisitions."
Historically, Thermo Fisher has achieved mid-single-digit organic revenue growth, augmented by a few percentage points via acquisitions. It also has enjoyed 20%-plus earnings growth. The company has spent a total of $900 million for a dozen acquisitions since the 2006 merger that created it, while also repurchasing $1.1 billion of stock. Yet Dekkers hints of a stronger current appetite for deals.
With shares of lab-supply leader Thermo Fisher Scientific down more than 40% from their 52-week high, investors have a great opportunity to buy the stock on the cheap.
"We have a lot of platforms and a long list of opportunities in lots of areas -- [potential] deals [totaling] in the billions that are best done for cash," he says, in elaborating on his balance-sheet strategy.
There is a chance that the Street's wariness about possible big acquisitions will continue to dampen enthusiasm for Thermo Fisher shares, which are roughly flat on the year. Like many big, high-quality stocks, they have largely sat out the recent rally.
And, for sure, other headwinds persist for the company. In the first quarter, cash-hoarding hospitals and university labs all but stopped buying routine supplies, producing an almost unheard-of inventory flush. Analysts say this phenomenon has continued to a degree this quarter, though it can't go on for long.
Big pharmaceutical mergers threaten to shut down redundant research-and-development projects, a minor concern. And the industrial segment remains quite weak, with many idled chemical and other plants sapping demand for certain products.
Yet by now, such factors appear well-incorporated into Thermo Fisher shares and the Street's newly tempered earnings expectations for this year. The company, in issuing preliminary guidance for 2010 last week, is using conservative assumptions for the timing and pace of any economic lift, and it's managing its costs accordingly.
The stock consistently garnered a premium multiple to the broad market before late last year -- sometimes as much as 40%. Currently, the stock is at a 10% discount to the Standard & Poor's 500 trailing and forward multiples.
Further, BCA Research notes that health-care-equipment stocks have a strong record as a leadership group exiting bear markets, and it points out that lean inventories and the continued growth in health-care-facility expansion are favorable.
The Obama stimulus package contains an allocation of billions for several research-and-development programs, which could supply a positive jolt to demand. More broadly, too, the increasing need for sophisticated diagnostics, tests, targeted drugs and environmental aids means Thermo Fisher is in an enviable position as the leading supplier for such needs.
Analyst sentiment toward Thermo Fisher is, admittedly, lopsidedly bullish, with all 13 analysts covering the company rating the shares a Buy. This is sometimes a concern for investors, when contrarian reasoning prevails. Yet the stock appears under-owned by institutions, given that its three largest shareholders are big passive index-fund firms: Barclays Global Investors, Vanguard Group and State Street.
The Bottom Line
Thermo Fisher Scientific shares have been mostly flat during this rally. But the balance sheet is solid, and there is plenty of room for investors to rediscover the stock.This suggests there remains room for investors to discover, or rediscover, the stock, which seems not to hold much downside risk in view of Thermo's balance-sheet strength. If there's increasing confidence that the company can reassert its growth path, the shares would easily merit a price/earnings multiple of 14 or better, which could push the stock up into the mid-40s as 2010 rolls into sight.
Even though the market has rallied 40% since March, a 30% potential gain for a high-quality stock should hold some appeal.
Stocks Discussed: TMO,